A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Conditions:   Melanoma;   Head and Neck Cancer;   Lymphoma;   Breast Cancer;   Pancreatic Cancer;   Liver Cancer;   Colon Cancer;   Lung Cancer;   Glioblastoma
Interventions:   Drug: INT230-6;   Biological: anti-PD-1;   Biological: anti-PD-1 antibody
Sponsors:   Intensity Therapeutics, Inc.;   University of Southern California;   University Health Network, Toronto
Recruiting - verified February 2017

http://ift.tt/2meJ6gE